Kory James Wentworth - Jul 10, 2023 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Chief Financial Officer
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Jul 10, 2023
Transactions value $
-$158,862
Form type
4
Date filed
7/12/2023, 04:34 PM
Previous filing
Jun 30, 2023
Next filing
Sep 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Options Exercise $12.8K +6.12K +16.64% $2.10* 42.9K Jul 10, 2023 Direct F1
transaction TRDA Common Stock Sale -$110K -6.12K -14.27% $17.98 36.7K Jul 10, 2023 Direct F1, F2
transaction TRDA Common Stock Options Exercise $8.16K +3.88K +10.57% $2.10* 40.6K Jul 11, 2023 Direct F1
transaction TRDA Common Stock Sale -$69.9K -3.88K -9.56% $18.00 36.7K Jul 11, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Stock Option (Right to Buy) Options Exercise $0 -6.12K -8.19% $0.00 68.5K Jul 10, 2023 Common Stock 6.12K $2.10 Direct F1, F4
transaction TRDA Stock Option (Right to Buy) Options Exercise $0 -3.88K -5.67% $0.00 64.7K Jul 11, 2023 Common Stock 3.88K $2.10 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.95 to $18.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.95 to $18.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.